Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge.

The X-ray crystal structures were solved for complexes with Torpedo californica acetylcholinesterase of two bivalent tacrine derivative compounds in which the two tacrine rings were separated by 5- and 7-carbon spacers. The derivative with the 7-carbon spacer spans the length of the active-site gorge, making sandwich interactions with aromatic residues both in the catalytic anionic site (Trp84 and Phe330) at the bottom of the gorge and at the peripheral anionic site near its mouth (Tyr70 and Trp279). The derivative with the 5-carbon spacer interacts in a similar manner at the bottom of the gorge, but the shorter tether precludes a sandwich interaction at the peripheral anionic site. Although the upper tacrine group does interact with Trp279, it displaces the phenyl residue of Phe331, thus causing a major rearrangement in the Trp279-Ser291 loop. The ability of this inhibitor to induce large-scale structural changes in the active-site gorge of acetylcholinesterase has significant implications for structure-based drug design because such conformational changes in the target enzyme are difficult to predict and to model.

[1]  Jan Kroon,et al.  STRATEGY: a program to optimize the starting spindle angle and scan range for X-ray data collection , 1997 .

[2]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[3]  Joel L Sussman,et al.  The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. , 2004, Journal of the American Chemical Society.

[4]  J L Sussman,et al.  Structure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution , 1999, FEBS letters.

[5]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[6]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[7]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[8]  Yuan-Ping Pang,et al.  Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies , 1994, J. Comput. Aided Mol. Des..

[9]  H. Fibiger,et al.  Chapter 49: Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia , 1993 .

[10]  S. French,et al.  On the treatment of negative intensity observations , 1978 .

[11]  S. Brimijoin,et al.  Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase , 1996, The Journal of Biological Chemistry.

[12]  B. P. Doctor,et al.  A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. , 1997, Biochemical and biophysical research communications.

[13]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[14]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[15]  I. Ivorra,et al.  The acetylcholinesterase inhibitor BW284c51 is a potent blocker of Torpedo nicotinic AchRs incorporated into the Xenopus oocyte membrane , 2005, British journal of pharmacology.

[16]  I B WILSON,et al.  The inhibitory effect of stilbamidine, curare and related compounds and its relationship to the active groups of acetylcholine esterase; action of stilbamidine upon nerve impulse conduction. , 1950, Biochimica et biophysica acta.

[17]  D. Humphrey,et al.  Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. , 1992, Molecular Pharmacology.

[18]  N. Greig,et al.  Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. , 2005, Journal of medicinal chemistry.

[19]  E. Giacobini,et al.  Cholinesterase inhibitors: new roles and therapeutic alternatives. , 2004, Pharmacological research.

[20]  Ettore Novellino,et al.  Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. , 2005, Journal of medicinal chemistry.

[21]  I Silman,et al.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. , 2001, Biochemistry.

[22]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[23]  G. Campiani,et al.  Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor. , 2006, Journal of the American Chemical Society.

[24]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[25]  H. Fibiger,et al.  Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. , 1993, Progress in brain research.

[26]  Axel T. Brunger,et al.  Free R value: cross-validation in crystallography. , 1997 .

[27]  Zoran Radić,et al.  In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors. , 2005, Journal of the American Chemical Society.

[28]  Zoran Radić,et al.  Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Sussman,et al.  Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. , 2005, Current opinion in pharmacology.

[30]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[31]  P. Carlier,et al.  Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. , 2004, Current pharmaceutical design.

[32]  P. Carlier,et al.  Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. , 1999, Journal of medicinal chemistry.

[33]  J. Sussman,et al.  Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. , 2003, Journal of molecular neuroscience : MN.

[34]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[35]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.

[36]  L. Austin,et al.  Two selective inhibitors of cholinesterase. , 1953, The Biochemical journal.

[37]  D. Boehr,et al.  Analysis of the pi-pi stacking interactions between the aminoglycoside antibiotic kinase APH(3')-IIIa and its nucleotide ligands. , 2002, Chemistry & biology.

[38]  J L Sussman,et al.  Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Vincenza Andrisano,et al.  Rational approach to discover multipotent anti-Alzheimer drugs. , 2005, Journal of medicinal chemistry.

[40]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[41]  Yuan-Ping Pang,et al.  Crystal packing mediates enantioselective ligand recognition at the peripheral site of acetylcholinesterase. , 2005, Journal of the American Chemical Society.

[42]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[43]  Ming-tao Li,et al.  Novel Dimeric Acetylcholinesterase Inhibitor Bis(7)-tacrine, but Not Donepezil, Prevents Glutamate-induced Neuronal Apoptosis by Blocking N-Methyl-d-aspartate Receptors* , 2005, Journal of Biological Chemistry.

[44]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[45]  M Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[46]  A T Brünger,et al.  Crystallographic refinement by simulated annealing: methods and applications. , 1997, Methods in enzymology.

[47]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[48]  E. Perry,et al.  Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment , 2005, Expert review of neurotherapeutics.

[49]  W. Jencks,et al.  Binding energy, specificity, and enzymic catalysis: the circe effect. , 2006, Advances in enzymology and related areas of molecular biology.

[50]  D. Neary,et al.  Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease , 1983, Journal of neurochemistry.

[51]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[52]  S. Wodak,et al.  Effect of mutations within the peripheral anionic site on the stability of acetylcholinesterase. , 1999, Molecular pharmacology.

[53]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Carlier,et al.  Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. , 1999, Bioorganic & medicinal chemistry.